Scientists working to develop diagnostic tests for neurological diseases have struggled for decades to identify biomarkers. Accessing diseased brain tissue to diagnose disease and match biofluids for biomarker discovery simply hasn't been possible.
Partnering with Reference Medicine, researchers can now obtain matched samples from large cohorts of diseased populations and isolate new markers to diagnose disease.
Reference Medicine partners with R&D teams that require tight, experimental control by providing large format specimens optimized for iterative experimentation.
By providing specimens in large volumes, developers can focus on manipulating assay variables in iterative experiments while mitigating sample variation.
We collect, process, and store specimens using diagnostic-grade workflows optimized to represent clinical conditions.
R&D teams rely on Reference Medicine for specimens that perform identically to patient samples to eliminate the costly risks associated with contrived specimens and cultured cells that produce false-negative or false-positive results during technology development, validation, or regulator submission.
Kindly inquire a conversation today.